Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
F. Li
Institution:
First Affiliated Hospital of Nanchang University
Observed institution:
First Affiliated Hospital of Nanchang University
ORCID:
0000-0003-2492-9909
Observed ORCID:
0000-0003-2492-9909
OpenAlex ID:
A5072545079
P1390: the Efficacy and Safety of Modified Melphalan and Busulfan-based Regimen for Allogeneic Transplantation in Refractory/relapsed Aml Patients
2022
·
S. Chen
, X. Zhang
, et al.
·
HemaSphere
·
2
MiR-137 contributes to drug susceptibility and chromosomal instability of multiple myeloma through targeting AURKA
2015
·
Y. Qin
, X. Qin
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
2
A PHASE IB STUDY OF AN ORAL PI3Kδ INHIBITOR LINPERLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA
2021
·
L. Qiu
, J. Jin
, et al.
·
Hematological Oncology
·
1
PDF
Pb1999: Atg-010 Plus Low-dose Dexamethasone (sd) in Chinese Relapsed/refractory Multiple Myeloma (rrmm) Patients Previously Received Chimeric Antigen Receptor T-cell (car-t)
2022
·
W. Fu
, Z. Xia
, et al.
·
HemaSphere
Pb1949: Eltrombopag in Chinese Patients With Refractory or Relapsed Severe Aplastic Anemia: a Non-randomized, Open-label, Multicenter, Phase Ii Study Assessing the Safety and Efficacy of Eltrombopag
2022
·
H. Chang
, G. He
, et al.
·
HemaSphere
Show more works
View as search
Works count:
5
Citation count:
5
H-index:
2
I10-index:
Year
Topic
Type